Summary

Description

The Frederick National Laboratory for Cancer Research (FNLCR) is developing the Advanced Technology Research Facility (ATRF), a new, 340,000 square foot translational R&D facility, consisting of advanced technology laboratories, biopharmaceutical development, and cGMP biopharmaceutical production facilities. The facility is designed to foster co-located partnership projects, with dedicated laboratory and "think tank" space for collaborative work with partners across a continuum of translational R&D technologies and platforms, including genomics, proteomics, nanotechnology, molecular diagnostics, bioinformatics, and biopharmaceutical development, and more. The ATRF will help bring together partners from the government, industry, academia, and the nonprofit sector to accelerate the translation of basic research findings into clinical technologies, diagnostics, and treatments for patients with cancer and AIDS. About one-third of the ATRF is available for partnership projects where the partner can co-locate resources thereby facilitating business and technology objectives of both the partners and the NCI. The Cancer Research Technology Program and the Biopharmaceutical Development Program are located in the new facility. The ATRF is the anchor facility of the National Cancer Institute at Riverside Research Park (RRP) . RRP is a premier biomedical research campus in Frederick, MD, which is growing through location of companies and organizations with complementary and synergistic technologies, products, services, and capabilities that are important to creating the next generation of therapies for cancer and AIDS. For further inquiries, please contact the Partnership Development Office